US tariffs Threaten $19 Billion Hit to European Pharmaceutical Industry, Sparking Calls for Reindustrialization
Table of Contents
A new report warns that escalating trade tensions with the United States could inflict an annual cost overrun of up to $19 billion on the European pharmaceutical industry, jeopardizing innovation, competitiveness, and patient access to vital treatments.
The analysis, conducted by LLYC, details the consequences of a 15% tariff imposed on brand-name drugs exported from the European Union – a departure from over three decades of tariff exemptions. Further compounding concerns is the potential for the tariffs to surge to 100% for companies lacking domestic US production facilities.
“The combination of tariffs and the pricing policy of the US governance adds high uncertainty to the business habitat of the European pharmaceutical industry,” the LLYC report states. The looming trade barriers are not merely a financial concern; they represent a fundamental shift in the global pharmaceutical landscape.
Spain Faces Heightened risk
The impact is expected to be especially acute for Spain, a growing pharmaceutical exporter. In 2024 alone, Spain shipped €1.095 billion worth of medicines to the United States, ranking among the nation’s top five export products. Tho, LLYC cautions that the new tariffs could erode Spain’s market share and negatively affect employment, particularly amid broader trade tensions and a potential relocation of investment to US soil.
The overall estimated impact of the new rates on the European pharmaceutical industry ranges from $13 billion to $19 billion annually. Farmaindustria, the Spanish pharmaceutical industry association, has already voiced its “concern” regarding the agreement between the EU and the US, citing a lack of clarity surrounding the tariff’s implementation. The association warns that increased tariffs could drive up medicine costs, disrupt supply chains, and stifle innovation.
According to Fina Lladó, president of Farmaindustria, the tariffs could inflate European production costs by €30 billion and perhaps discourage investment projects totaling €100 billion over the next four years. A significant vulnerability lies in the fact that 24% of the raw materials used in European pharmaceutical manufacturing originate in the United States.
Innovation and Access to Medicines at Stake
The report emphasizes that the financial burden of these trade measures extends beyond immediate costs. The imposition of tariffs could also delay the introduction of groundbreaking therapies to European markets. Estimates from the European Federation of Pharmaceutical Industries and Associations (Efpia) suggest that tariffs will directly impact investment margins and research and progress (R&D) projects,ultimately hindering competitiveness and limiting treatment availability.
Adding to the complexity is the US’s Most Favored Nation (MFN) pricing policy, which aims to align drug prices in the US with the lowest prices found in OECD countries. LLYC warns that strict enforcement of this policy could pressure European nations to accept higher drug prices, straining healthcare budgets and delaying patient access to new medications.
“If European governments do not act in a coordinated manner and create real incentives, the main losers will be patients, who will see their access to innovative treatments and medicines limited,” the report concludes.
A Catalyst for European Pharmaceutical Autonomy?
Despite the significant challenges, LLYC identifies a potential prospect for Europe to bolster its strategic autonomy and pursue a unified industrial policy. The current situation could incentivize new investments in production,biotechnology,and clinical trials,particularly in countries like Spain and Portugal,provided stable legislative and financial frameworks are established.
The Spanish government has already launched a €14 billion Response Plan and Commercial Relaunch aimed at mitigating the effects of US tariffs and supporting exporting companies. While the plan does not specifically target the pharmaceutical sector,LLYC believes it will strengthen Spain’s ability to maintain exports and attract industrial investment.
The report ultimately frames the US tariff policies as both a structural challenge and a catalyst for reindustrializing the European pharmaceutical sector and enhancing its resilience. “Europe must play by the same rules of the game as the United States,” states Carlos Parry, Europe Healthcare Lead at LLYC. “Only in this way will it guarantee that innovation reaches patients and that the sector continues to generate investment, employment and economic growth.”
- RAP vs. IBR: What Your New Student Loan Bill Actually Costs (daybreakwire.com)
